Literature DB >> 19468817

Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.

Virgili Pérez1, Victoria Sosti, Antonia Rubio, Manel Barbanoj, Ignasi Gich, José Rodríguez-Alvarez, Jaime Kulisevsky.   

Abstract

A decrease in noradrenergic activity in Parkinson's disease might play a critical role in long-term motor complications associated with chronic dopaminergic replacement. Using the rat model of parkinsonism with an additional noradrenergic degeneration induced by the N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) toxin we evaluated whether the circling motor activity and dose-failure episodes induced by levodopa (L-DOPA) differ between single (6-OHDA) and double (6-OHDA + DSP-4) denervated animals challenged with a single daily dose of L-DOPA. While single-lesioned animals showed a sensitization-desensitization turning response with a significant increase on day 15 and a decrease on day 22, in double-lesioned animals, the turning activity was maximal from day 1 and did not decay on day 22. Double-lesioned rats exhibited significantly higher number of turns on days 15 and 22 and a significantly lower percentage of dose-failure episodes during treatment. Noradrenergic denervation appears to be associated with prolonged long-term dopaminergic sensitization. This type of response appears to be comparable to that in the clinical setting with intermittent L-DOPA administration where no desensitization occurs once the abnormal response is established.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19468817     DOI: 10.1007/s00702-009-0242-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  59 in total

1.  Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling.

Authors:  Bogachan Sahin; Stacey Galdi; Joseph Hendrick; Robert W Greene; Gretchen L Snyder; James A Bibb
Journal:  Brain Res       Date:  2006-12-06       Impact factor: 3.252

2.  Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.

Authors:  J Srinivasan; W J Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

3.  Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats.

Authors:  C Marin; E Aguilar; M Bonastre
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

4.  Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas.

Authors:  P Svenningsson; C Le Moine; B Kull; R Sunahara; B Bloch; B B Fredholm
Journal:  Neuroscience       Date:  1997-10       Impact factor: 3.590

5.  PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.

Authors:  Virgili Perez; Mercedes Unzeta
Journal:  Neurochem Int       Date:  2003-02       Impact factor: 3.921

6.  Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.

Authors:  C Marin; A Jimenez; M Bonastre; T N Chase; E Tolosa
Journal:  Synapse       Date:  2000-06-15       Impact factor: 2.562

7.  Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Authors:  Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurster; Steven G McGuire; Susan H Fox; Alan R Crossman; Jonathan M Brotchie
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

8.  Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.

Authors:  Christine Konradi; Jenny E Westin; Manolo Carta; Molly E Eaton; Katarzyna Kuter; Andrzej Dekundy; Martin Lundblad; M Angela Cenci
Journal:  Neurobiol Dis       Date:  2004-11       Impact factor: 5.996

9.  Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  C Marin; E Aguilar; M C Rodríguez-Oroz; G D Bartoszyk; J A Obeso
Journal:  Psychopharmacology (Berl)       Date:  2009-01-22       Impact factor: 4.530

Review 10.  Levodopa-induced dyskinesias.

Authors:  Giovanni Fabbrini; Jonathan M Brotchie; Francisco Grandas; Masahiro Nomoto; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-07-30       Impact factor: 10.338

View more
  3 in total

1.  Loss of Brain Norepinephrine Elicits Neuroinflammation-Mediated Oxidative Injury and Selective Caudo-Rostral Neurodegeneration.

Authors:  Sheng Song; Lulu Jiang; Esteban A Oyarzabal; Belinda Wilson; Zibo Li; Yen-Yu Ian Shih; Qingshan Wang; Jau-Shyong Hong
Journal:  Mol Neurobiol       Date:  2018-07-27       Impact factor: 5.590

2.  Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.

Authors:  Christopher J Barnum; Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Stefanie Tignor; Anna Klioueva; Hannah Walters; Christopher Bishop
Journal:  Pharmacol Biochem Behav       Date:  2011-09-25       Impact factor: 3.533

3.  Noradrenaline and Parkinson's disease.

Authors:  Claire Delaville; Philippe De Deurwaerdère; Abdelhamid Benazzouz
Journal:  Front Syst Neurosci       Date:  2011-05-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.